FOUNDATIONONE®CDx

PATIENT
Lu, Ming-Tung

TUMOR TYPE
Pancreas ductal adenocarcinoma
COUNTRY CODE
TW

REPORT DATE
06 Jan 2022
ORDERED TEST #
ORD-1269992-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Pancreas ductal adenocarcinoma
NAME Lu, Ming-Tung
DATE OF BIRTH 10 November 1960
SEX Male
MEDICAL RECORD # 42092591

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN SITE Pancreas
SPECIMEN ID S110-62338D
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 15 December 2021
SPECIMEN RECEIVED 29 December 2021

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 1 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

KRAS G12D
SF3B1 R625H
TP53 H179L

2 Disease relevant genes with no reportable alterations: *BRCA1, BRCA2*

† See About the Test in appendix for details.

Report Highlights

- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 7)
- Variants that may represent **clonal hematopoiesis** and may originate from non-tumor sources: ***SF3B1*** **R625H** (p. 5)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS	
Microsatellite status - MS-Stable	**No therapies or clinical trials.** see Biomarker Findings section	
Tumor Mutational Burden - 1 Muts/Mb	**No therapies or clinical trials.** see Biomarker Findings section	
GENOMIC FINDINGS	**THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)**	**THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)**
***KRAS* -** G12D	none	none
3 Trials *see p. 7*		

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS (CH)

Genomic findings below may include nontumor somatic alterations, such as CH. The efficacy of targeting such nontumor somatic alterations is unknown. This content should be interpreted based on clinical context. Refer to appendix for additional information on CH.

SF3B1 - R625H ..... p. 5

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

SF3B1 - R625H ..... p. 5 ***TP53*** - H179L ..... p. 6

Electronically signed by Erik Williams, M.D. | 06 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Sample Analysis: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Electronically signed by Erik Williams, M.D. | 06 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Sample Analysis: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

MSI is rare in pancreatic carcinoma, reported in less than 1% of samples (n=>1,000)[6-10]. The prognostic significance of MSI in pancreatic cancer is unknown (PubMed, Aug 2021).

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[11]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[11-13]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[14-16]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[11,13,15-16].

BIOMARKER

Tumor Mutational Burden

RESULT
1 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[17-19], anti-PD-1 therapies[17-20], and combination nivolumab and ipilimumab[21-26]. In multiple pan-tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors[17-20,27]. Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors[17]. Analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16-20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy, compared with patients with higher TMB treated with chemotherapy[28] or those with lower TMB treated with PD-1 or PD-L1-targeting agents[18]. However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB ≥10 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials[20,27]. Together, these studies suggest that patients with TMB ≥10 Muts/Mb may derive clinical benefit from PD-1 or PD-L1 inhibitors.

FREQUENCY & PROGNOSIS

Pancreatic carcinomas, including ductal and acinar subtypes, have been reported to harbor a median TMB of 2-3 mutations per megabase (muts/Mb), and 0-2% of cases have high TMB (>20 muts/Mb)[29]; TMB has not been assessed in pancreatic mucinous neoplasms (PubMed, Oct 2021). A study of patients with pancreatic ductal adenocarcinoma harboring mismatch repair gene mutations reported improved prognosis for patients with high TMB measured in tissue samples (defined as >50 mutations; survival 69-314 months) compared to those with lower TMB (average of 5.7 mutations; 10-42 months)[30].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[31-32] and cigarette smoke in lung cancer[33-34], treatment with temozolomide-based chemotherapy in glioma[35-36], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[37-41], and microsatellite instability (MSI)[37,40-41]. This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types[18-19,27].

Electronically signed by Erik Williams, M.D. | 06 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Sample Analysis: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
KRAS

ALTERATION
G12D

TRANSCRIPT ID
NM_004985

CODING SEQUENCE EFFECT
35G>A

VARIANT ALLELE FREQUENCY (% VAF)
14.5%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

In a Phase 1 study evaluating the MEK-pan-RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non-small cell lung cancer (NCSLC), 1 with low-grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma[42]. Another Phase 1 study of CH5126766 combined with the FAK inhibitor defactinib reported 4 PRs in KRAS-mutated LGSOC[43]. Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors[44-45]. A Phase 1 study of RMC-4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations[46]. Interim results from a Phase 1/2 study of RMC-4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS-mutated colorectal cancer[47]. Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib[48-53]. Initial Phase 1 monotherapy trials of MEK inhibitors in patients with pancreatic cancer showed promise, with DCR (PR and/or SD) up to 37%[54], response rates up to 25%[54-58], and prolonged PRs in certain patients[55,57,59]. However, subsequent clinical trials combining various MEK inhibitors with gemcitabine reported no additional benefit compared to gemcitabine alone irrespective of KRAS mutation status[60-63], with refametinib and gemcitabine even showing a trend towards worse response and survival in patients with KRAS-mutant pancreatic tumors than in those with KRAS wild-type tumors (OS 6.6 months vs 18.2 months)[60]. Trials combining MEK inhibitors with other targeted therapies, such as EGFR inhibitors[64] or PI3K-AKT pathway inhibitors[65-66], reported no PRs and frequent adverse events in patients with KRAS-mutant pancreatic cancer. Emerging preclinical studies suggest MEK inhibition downstream of KRAS-mutant pancreatic tumors leads to increased autophagy[67-68]. Combination MEK/autophagy inhibitors may therefore be more beneficial. A heavily pretreated patient with pancreatic cancer treated with trametinib plus hydroxychloroquine exhibited a PR[67]. A Phase 2 trial of paclitaxel/carboplatin with or without Reolysin in patients with metastatic pancreatic adenocarcinoma reported no improvement in PFS with addition of Reolysin, regardless of KRAS mutational status[69]; however a Phase 2 study of Reolysin and gemcitabine in patents with pancreatic cancer reported 1 PR, 23 SDs, and 5 PDs in 34 patients with a favorable median OS of 10.2 months[70]. Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors[71-72]. Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations[73-74] .

FREQUENCY & PROGNOSIS

KRAS mutations have been observed in 91-95% of pancreatic ductal adenocarcinoma cases[75-76], with the majority of mutations found at codon 12[77-80]. KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma[78].

FINDING SUMMARY

KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation[49,81]. KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, R68S, and K117N have been characterized as activating and oncogenic[49,82-104].

GENE
SF3B1

ALTERATION
R625H

TRANSCRIPT ID
NM_012433

CODING SEQUENCE EFFECT
1874G>A

VARIANT ALLELE FREQUENCY (% VAF)
11.3%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical studies suggest that mutations in genes encoding spliceosome components, including SF3B1, may confer sensitivity to spliceosome inhibitors[105-109]. In preclinical models, SF3B1 mutation leads to DNA damage and ATR-CHK1 pathway activation, increasing sensitivity to ATR and CHK1 inhibitors[109]. However, clinical data supporting SF3B1 as biomarkers for the efficacy of these approaches is lacking.

FREQUENCY & PROGNOSIS

In the context of solid tumors, SF3B1 mutation has been reported in adenoid cystic carcinomas of the salivary gland (4%, 1/24)[110] and breast[111] as well as in pancreatic carcinoma[75], glioblastoma, and renal clear cell carcinoma[112]. Mutation of SF3B1 was found to be recurrent in several breast carcinoma subtypes[113-115], and in unselected breast cancers, it correlated with ER-positivity and frequent co-occurrence with AKT1 and PIK3CA mutations[114,116]. The hot spot mutation K700E was found in 16% (3/19) of papillary and 6% of breast mucinous carcinomas[116]. In solid tumors, the prognostic implications of SF3B1 alterations are dependent on disease context. In a study of 3282 breast cancer cases, SF3B1 mutation was significantly associated with a poor prognosis for patients with luminal B and progesterone receptor (PR)-negative subtypes of disease[117]. For patients with hepatocellular carcinoma, one study showed that SF3B1 mutation was associated with an advanced stage of disease[118]. However, in one study of primary uveal melanoma, SF3B1 mutation was correlated with improved PFS[119].

FINDING SUMMARY

SF3B1 encodes a subunit of the spliceosome, the complex that is responsible for the splicing of pre-mRNA molecules to create mature messenger RNA[120-123]. SF3B1 mutations predominantly occur in HEAT domains 5-7 at codons 625, 662, 666, and 700[116,124-128], which result in neomorphic activity that upregulates aberrant mRNA splicing[129-132]. The consequences of SF3B1 alterations outside of these sites have not been extensively characterized.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[112,133-137]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[133-134]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[138]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[136,139-140]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

GENE
TP53

ALTERATION
H179L

TRANSCRIPT ID
NM_000546

CODING SEQUENCE EFFECT
536A>T

VARIANT ALLELE FREQUENCY (% VAF)
30.2%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[141-144], or p53 gene therapy and immunotherapeutics such as SGT-53[145-149] and ALT-801[150]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) for patients with TP53 mutations versus 12.1% (4/33) for patients who were TP53 wild-type[151]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[152]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer[153]. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[154]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel[155]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations[156]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[149]. Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53-mutated, but not TP53-wild-type, breast cancer xenotransplant mouse model[157]. Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR-246[158-160]. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, APR-246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR[161]. ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies[162-163]; however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies[164-165]. Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition.

FREQUENCY & PROGNOSIS

TP53 mutations have been reported in 33-75% of pancreatic carcinomas, with the majority occurring as missense mutations, while deletion of TP53 has been found in 66% of pancreatic ductal adenocarcinoma cases[75,166-168]. TP53 mutations are common in pancreatic ductal adenocarcinomas and are known to occur in the process of pancreatic carcinogenesis[169-170]. Additionally, aberrant expression of p53 has been found in 54-81% of pancreatic ductal adenocarcinoma cases[167,171-173]. Studies have found inconsistent results regarding the prognostic significance of p53 expression in pancreatic ductal adenocarcinoma, although one study correlated low levels of TP53 mRNA with poor patient prognosis[171,174-175].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[176]. Alterations such as seen here may disrupt TP53 function or expression[177-181].

POTENTIAL GERMLINE IMPLICATIONS

Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[182-184], including sarcomas[185-186]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[187] to 1:20,000[186]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[188]. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[112,133-137]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[133-134]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[138]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[136,139-140]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Electronically signed by Erik Williams, M.D. | 06 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Sample Analysis: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
KRAS

ALTERATION
G12D

RATIONALE
KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK-pan-RAF dual inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS-mutant pancreatic cancer. Emerging data suggest patients with KRAS-mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors.

NCT04111458

PHASE 1

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

TARGETS
KRAS, SOS1, MEK

LOCATIONS: Frankfurt am Main (Germany), Köln (Germany), Utrecht (Netherlands), Rotterdam (Netherlands), Massachusetts, Tennessee, Texas, North Carolina

NCT03825289

PHASE 1

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

TARGETS
MEK

LOCATIONS: Utah

NCT04132505

PHASE 1

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

TARGETS
MEK

LOCATIONS: Texas

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

DDR1
L507V

FLT3
G64R

MITF
E207G

MLL2
T698_P706del

PARK2
C441R

PDCD1LG2 (PD-L2)
K255E

PIK3CB
R847C

Electronically signed by Erik Williams, M.D. | 06 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Sample Preparation: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B)*	*APC*
AR	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*	*BTG2*
BTK	*C11orf30 (EMSY)*	*C17orf39 (GID4)*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*
CCND2	*CCND3*	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*
CDH1	*CDK12*	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FAM46C	*FANCA*	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*
FGF14	*FGF19*	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*
FGFR4	*FH*	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*
GATA4	*GATA6*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3F3A*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11A*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*	*P2RY8*	*PALB2*
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*	*PDGFRA*
PDGFRB	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*	*REL*	*RET*
RICTOR	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*	*SDHD*	*SETD2*
SF3B1	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*	*SNCAIP*	*SOCS1*
SOX2	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*	*STK11*	*SUFU*
SYK	*TBX3*	*TEK*	*TET2*	*TGFBR2*	*TIPARP*	*TNFAIP3*	*TNFRSF14*	*TP53*
TSC1	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*	*VHL*	*WHSC1*	*WT1*	*XPO1*
XRCC2	*ZNF217*	*ZNF703*						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV4*
ETV5	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*	*KMT2A (MLL)*
MSH2	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*	*RAF1*
RARA	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***	*TMPRSS2*

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-

Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
4. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
5. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
6. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear

cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.2.0

The median exon coverage for this sample is 1,132x

Electronically signed by Erik Williams, M.D. | 06 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Sample Preparation: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Hu ZI, et al. Clin. Cancer Res. (2018) pmid: 29367431
7. Campbell BB, et al. Cell (2017) pmid: 29056344
8. Pihlak R, et al. Cancers (Basel) (2018) pmid: 29329208
9. Salem ME, et al. Mol. Cancer Res. (2018) pmid: 29523759
10. Laghi L, et al. PLoS ONE (2012) pmid: 23029359
11. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
12. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
13. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
14. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
15. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
16. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
17. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
18. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
19. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
20. Cristescu R, et al. Science (2018) pmid: 30309915
21. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
22. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
23. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
24. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
25. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
26. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
27. Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526
28. Legrand et al., 2018; ASCO Abstract 12000
29. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
30. Hu et al., 2017; ASCO Abstract e15791
31. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
32. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
33. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
34. Rizvi NA, et al. Science (2015) pmid: 25765070
35. Johnson BE, et al. Science (2014) pmid: 24336570
36. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
37. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
38. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
39. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
40. Nature (2012) pmid: 22810696
41. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
42. Norton ML, et al. Leg Med (1986) pmid: 3312887
43. Shinde et al., 2020; AACR Abstract CT143
44. Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384
45. Mainardi S, et al. Nat Med (2018) pmid: 29808006
46. Koczywas et al., 2021; AACR Abstract LB001
47. Bendell et al., 2020; EORTC-NCI-AACR Abstract 5
48. Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174
49. Pylayeva-Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244
50. Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318
51. Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367
52. Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089
53. Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556
54. Bodoky G, et al. Invest New Drugs (2012) pmid: 21594619
55. Rinehart J, et al. J. Clin. Oncol. (2004) pmid: 15483017
56. Lorusso PM, et al. J. Clin. Oncol. (2005) pmid: 16009947
57. Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291
58. Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733
59. Garrido-Laguna I, et al. Oncoscience (2015) pmid: 25897431
60. Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152
61. Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440
62. Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778
63. Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206
64. Ko AH, et al. Clin. Cancer Res. (2016) pmid: 26251290
65. Chung V, et al. JAMA Oncol (2017) pmid: 27978579
66. Bedard PL, et al. Clin. Cancer Res. (2015) pmid: 25500057
67. Kinsey CG, et al. Nat. Med. (2019) pmid: 30833748
68. Bryant KL, et al. Nat. Med. (2019) pmid: 30833752
69. Noonan AM, et al. Mol. Ther. (2016) pmid: 27039845
70. Mahalingam D, et al. Cancers (Basel) (2018) pmid: 29799479
71. Hillig RC, et al. Proc Natl Acad Sci U S A (2019) pmid: 30683722
72. Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843
73. Hofmann et al., 2021; AACR Abstract CT210
74. Gort et al., 2020; ASCO Abstract TPS3651
75. Biankin AV, et al. Nature (2012) pmid: 23103869
76. Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536
77. Feldmann G, et al. J Hepatobiliary Pancreat Surg (2007) pmid: 17520196
78. Rachakonda PS, et al. PLoS ONE (2013) pmid: 23565280
79. Hruban RH, et al. Am. J. Pathol. (1993) pmid: 8342602
80. Maitra A, et al. Best Pract Res Clin Gastroenterol (2006) pmid: 16549325
81. Kahn S, et al. Anticancer Res. () pmid: 3310850
82. Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185
83. Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068
84. Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776
85. Sci. STKE (2004) pmid: 15367757
86. Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076
87. Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178
88. Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621
89. Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890
90. Kim E, et al. Cancer Discov (2016) pmid: 27147599
91. Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576
92. Naguib A, et al. J Mol Signal (2011) pmid: 21371307
93. Prior IA, et al. Cancer Res. (2012) pmid: 22589270
94. Privé GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661
95. Scheffzek K, et al. Science (1997) pmid: 9219684
96. Scholl C, et al. Cell (2009) pmid: 19490892
97. Smith G, et al. Br. J. Cancer (2010) pmid: 20147967
98. Tyner JW, et al. Blood (2009) pmid: 19075190
99. Valencia A, et al. Biochemistry (1991) pmid: 2029511
100. White Y, et al. Nat Commun (2016) pmid: 26854029
101. Wiest JS, et al. Oncogene (1994) pmid: 8058307
102. Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513
103. Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870
104. Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033
105. Obeng EA, et al. Cancer Cell (2016) pmid: 27622333
106. Lee SC, et al. Nat. Med. (2016) pmid: 27135740
107. Yoshimi A, et al. Clin. Cancer Res. (2017) pmid: 27836865
108. Lee SC, et al. Nat. Med. (2016) pmid: 27603132
109. Singh S, et al. Leukemia (2020) pmid: 32076118
110. Stephens PJ, et al. J. Clin. Invest. (2013) pmid: 23778141
111. Martelotto LG, et al. J. Pathol. (2015) pmid: 26095796
112. Xie M, et al. Nat. Med. (2014) pmid: 25326804
113. Banerji S, et al. Nature (2012) pmid: 22722202
114. Ellis MJ, et al. Nature (2012) pmid: 22722193
115. Nature (2012) pmid: 23000897
116. Maguire SL, et al. J. Pathol. (2015) pmid: 25424858
117. Fu X, et al. Oncotarget (2017) pmid: 29383138
118. Nault JC, et al. Hepatology (2020) pmid: 31206197
119. Furney SJ, et al. Cancer Discov (2013) pmid: 23861464
120. Wang C, et al. Genes Dev. (1998) pmid: 9585501
121. Quesada V, et al. Nat. Genet. (2011) pmid: 22158541
122. Wang L, et al. N. Engl. J. Med. (2011) pmid: 22150006
123. Visconte V, et al. Blood (2012) pmid: 22826563
124. Hahn CN, et al. Nat. Genet. (2011) pmid: 22200771
125. Rossi D, et al. Blood (2011) pmid: 22039264
126. Yang J, et al. Genet Test Mol Biomarkers (2013) pmid: 23390883
127. Patnaik MM, et al. Blood (2012) pmid: 22096241
128. Wan Y, et al. Blood (2013) pmid: 23568491
129. Gentien D, et al. Leukemia (2014) pmid: 24434863
130. Schmidt M, et al. Diabetes Res. (1989) pmid: 2576898
131. Darman RB, et al. Cell Rep (2015) pmid: 26565915
132. Alsafadi S, et al. Nat Commun (2016) pmid: 26842708
133. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
134. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
135. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
136. Severson EA, et al. Blood (2018) pmid: 29678827
137. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
138. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
139. Chabon JJ, et al. Nature (2020) pmid: 32269342
140. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
141. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
142. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
143. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100
144. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
145. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
146. Xu L, et al. Mol. Med. (2001) pmid: 11713371
147. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
148. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
149. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628
150. Hajdenberg et al., 2012; ASCO Abstract e15010
151. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
152. Moore et al., 2019; ASCO Abstract 5513

Electronically signed by Erik Williams, M.D. | 06 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Sample Preparation: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

153. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
154. Oza et al., 2015; ASCO Abstract 5506
155. Lee J, et al. Cancer Discov (2019) pmid: 31315834
156. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
157. Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188
158. Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953
159. Mohell N, et al. Cell Death Dis (2015) pmid: 26086967
160. Fransson Å, et al. J Ovarian Res (2016) pmid: 27179933
161. Gourley et al., 2016; ASCO Abstract 5571
162. Kwok M, et al. Blood (2016) pmid: 26563132
163. Boudny M, et al. Haematologica (2019) pmid: 30975914
164. Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704
165. Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241
166. Morton JP, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20018721
167. Scarpa A, et al. Am. J. Pathol. (1993) pmid: 8494051
168. Luo Y, et al. Pathol. Oncol. Res. (2013) pmid: 22782330
169. Iacobuzio-Donahue CA, et al. Clin. Cancer Res. (2012) pmid: 22896692
170. Macgregor-Das AM, et al. J Surg Oncol (2013) pmid: 22806689
171. Oshima M, et al. Ann. Surg. (2013) pmid: 23470568
172. Ottenhof NA, et al. Cell Oncol (Dordr) (2012) pmid: 22351431
173. Tsiambas E, et al. J BUON () pmid: 20414934
174. Ansari D, et al. Br J Surg (2011) pmid: 21644238
175. Grochola LF, et al. Pancreas (2011) pmid: 21404460
176. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
177. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
178. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
179. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
180. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
181. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
182. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
183. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
184. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
185. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
186. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
187. Lalloo F, et al. Lancet (2003) pmid: 12672316
188. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713

Electronically signed by Erik Williams, M.D. | 06 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Sample Preparation: 7010 Kit Creek Road, Morrisville, NC 27560 · CLIA: 34D2044309
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531